Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DAO | P14920 | 1/20 | 0.43 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.43 |
| ▸ | HTR2A | P28223 | 2/20 | 0.42 |
| ▸ | HTR2C | P28335 | 2/20 | 0.42 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.38 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.37 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.37 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.34 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.34 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.34 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.34 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.34 |
| ▸ | HTR2B | P41595 | 1/20 | 0.34 |
| ▸ | GRM5 | P41594 | 1/20 | 0.33 |
| ▸ | BRD4 | O60885 | 1/20 | 0.33 |
| ▸ | PDE4A | P27815 | 4/20 | 0.33 |
| ▸ | PDE4B | Q07343 | 4/20 | 0.33 |
| ▸ | PDE4C | Q08493 | 4/20 | 0.33 |
| ▸ | PDE4D | Q08499 | 4/20 | 0.33 |
| ▸ | PDE3B | Q13370 | 3/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3791475 | 0.89 | DAO (0.41) | DAOCYP2A6HTR2AHTR2CCYP19A1 | |
| SCHEMBL2610672 | 0.84 | CYP2A6 (0.50) | DAOCYP2A6HTR2AHTR2CCYP19A1 | |
| SCHEMBL11005622 | 0.81 | DAO (0.43) | DAOCYP2A6HTR2AHTR2CCYP19A1 | |
| SCHEMBL8504667 | 0.80 | HTR2A (0.48) | DAOCYP2A6HTR2AHTR2CCYP19A1 | |
| SCHEMBL3625379 | 0.78 | CYP19A1 (0.48) | DAOCYP2A6HTR2AHTR2CCYP19A1 | |
| SCHEMBL2097238 | 0.77 | DAO (0.40) | DAOCYP2A6HTR2AHTR2CCYP19A1 | |
| SCHEMBL3154995 | 0.76 | CYP2A6 (0.46) | DAOCYP2A6HTR2AHTR2CCYP19A1 | |
| SCHEMBL113854 | 0.76 | CYP2A6 (0.46) | DAOCYP2A6HTR2AHTR2CCYP19A1 | |
| SCHEMBL12432195 | 0.76 | CYP2A6 (0.46) | DAOCYP2A6HTR2AHTR2CCYP19A1 | |
| SCHEMBL3056444 | 0.76 | CYP2A6 (0.46) | DAOCYP2A6HTR2AHTR2CCYP19A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11492352-B2 | Arenavirus growth inhibitor comprising polycyclic carbamoylpyridone derivative | NATIONAL UNIVERSITY CORPORATION HOKKAIDO UNIVERSITY (JP) | 2022-11-08 | — | — | US | disclosed |
| US-20210292321-A1 | ARENAVIRUS GROWTH INHIBITOR COMPRISING POLYCYCLIC CARBAMOYL PYRIDONE DERIVATIVE | NATIONAL UNIVERSITY CORPORATION HOKKAIDO UNIVERSITY (JP) | 2021-09-23 | — | — | US | disclosed |
| EP-3815689-A1 | ARENAVIRUS GROWTH INHIBITOR COMPRISING POLYCYCLIC CARBAMOYL PYRIDONE DERIVATIVE | National University Corporation Hokkaido University (JP) | 2021-05-05 | — | — | EP | disclosed |
| US-10544419-B2 | PDGF and VEGF aptamers having improved stability and their use in treating PDGF and VEGF mediated diseases and disorders | SOMALOGIC INC. (US) | 2020-01-28 | — | — | US | disclosed |
| US-9994857-B2 | PDGF and VEGF aptamers having improved stability and their use in treating PDGF and VEGF mediated diseases and disorders | SOMALOGIC, INC. (US) | 2018-06-12 | — | — | US | disclosed |
| US-20170260531-A1 | Aptamers to PDGF and VEGF and Their Use in Treating PDGF and VEGF Mediated Conditions | SOMALOGIC OPERATING CO. INC. | 2017-09-14 | — | — | US | disclosed |
| US-20120108566-A1 | NICOTINAMIDES AS JAK KINASE MODULATORS | PORTOLA PHARMACEUTICALS, INC. (US) | 2012-05-03 | — | — | US | disclosed |
| US-7645400-B2 | Composition containing carbon nanotubes having a coating | MITSUBISHI RAYON CO., LTD. (JP) | 2010-01-12 | — | — | US | disclosed |
| US-20090321688-A1 | Carbon Nanotube Composition, Composite Having a Coated Film Composed of the Same, and Their Production Methods | MITSUBISHI RAYON CO., LTD. (JP) | 2009-12-31 | — | — | US | disclosed |
| US-20060052509-A1 | Composition containing carbon nanotubes having coating thereof and process for producing them | MITSUBISHI RAYON CO., LTD. (JP) | 2006-03-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11492352-B2 | Arenavirus growth inhibitor comprising polycyclic carbamoylpyridone derivative | LUC7L2, CXCR6, RRP12 | DAO 3243/4885CYP2A6 1210/4885HTR2A 3531/4885 |
| US-20210292321-A1 | ARENAVIRUS GROWTH INHIBITOR COMPRISING POLYCYCLIC CARBAMOYL PYRIDONE DERIVATIVE | CCNA1, CDK7, CCR10 | DAO 3085/4885CYP2A6 1040/4885HTR2A 3479/4885 |
| US-20120108566-A1 | NICOTINAMIDES AS JAK KINASE MODULATORS | JAK2, JAK1, NADK | DAO 1167/4885CYP2A6 1003/4885HTR2A 3280/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.